| Name | Title | Contact Details |
|---|
Peoples Health is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Circle Health Services, now affiliated with The Centers for Families and Children, is a nonprofit Federally Qualified Health Center (FQHC) that provides high-quality health care and related services to individuals and families regardless of their ability to pay. The Circle Health Services community health center, located at 12201 Euclid Avenue, is a 34,000 sq. ft. facility equipped with 18 examination rooms, five dental chairs, multiple group and individual therapy rooms, and an in-house pharmaceutical dispensary. The health center offers Adult and Pediatric Primary Care, a Teen/Reproductive Health Clinic, Dental Services, Behavioral Health Clinic, HIV Services, Dental Services, and Project DAWN (Deaths Avoided with Naloxone). Circle Health also operates a mobile syringe exchange program. Today, through its affiliation with The Centers for Families and Children, Circle Health operates under a shared leadership structure, which allows the organizations integrate behind-the-scenes administrative and operational support work and provide employees of both organizations access to the same benefits and professional development. Together, the organizations serve nearly 30,000 people and have more than 600 employees.
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
California MedTech is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.